Understanding Cardiovascular Events With JAK Inhibitors: Similarities and Differences of the Vascular Effects Between Different JAK Inhibitors on Endothelial Cells Exposed to Inflammatory Cytokines.

ABSTRACT:

Objective

A cardiovascular safety issue has been associated with JAK inhibitors (JAKi). This study compares the effects of distinct approved JAKi on endothelial cell (EC) dysfunction and apoptosis during inflammation.

Methods

Massive inflammation was induced in human vascular ECs by tumor necrosis factor (TNF) with interleukin-17A (IL-17A) treated or not treated with tofacitinib, baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib at 1 or 10 μM. Levels of IL-6 and IL-8 were measured by enzyme-linked immunosorbent assay. Variations in gene expression of adhesion molecules and factors of blood coagulation and fibrinolysis pathways were quantified by quantitative reverse transcriptase-polymerase chain reaction. Endothelial apoptosis was measured by Annexin V sta

SUBMITTER: Zavoriti A 

PROVIDER: S-EPMC12678200 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature